Home »
Academic Articles & Research Papers
Showing 13 of 13 academic articles
Rayner CR, Martin NE, Smith D, Kruger E et al. • Clinical pharmacology and therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1002/cpt.70476
PMC: PMC13547536
van Rensburg R, Pillay-Fuentes Lorente V, Decloedt E • Clinical pharmacology and therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1002/cpt.70494
PMC: PMC13599374
Sattayalertyanyong O, Nugent Z, Barr B, Bernstein KN et al. • Alimentary pharmacology & therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1111/apt.70845
PMC: PMC13603951
Eke AC • Clinical pharmacology and therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1002/cpt.70520
PMC: PMC13650961
Girotto JE, Warminski S, Fly JH, Forster J et al. • The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.5863/JPPT-26-00035
PMC: PMC13657064
Kumari N, Shukla SK, Thakur R • Pharmacology & therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1016/j.pharmthera.2026.109109
PMC: PMC13711273
Mitra A, Dosne AG, Steinbach D, Jones HM et al. • Clinical pharmacology and therapeutics
(2026)
PMC
PMC Public Access (View-Only)
DOI: 10.1002/cpt.70548
PMC: PMC13723151
Man Luo, Man Luo, Man Luo, Jiang Zhu et al. • Frontiers in Pharmacology
(2025)
BackgroundDrug repurposing has emerged as a promising approach for discovering novel anticancer therapeutics. In this study, we systematically investigated the antitumor potential of fedratinib, a JAK2 inhibitor approved for myelofibrosis, ...
DOAJ
Open Access (DOAJ)
DOI: 10.3389/fphar.2025.1689663
Yundong He, Ting Wei, Zhenqing Ye, Jacob J. Orme et al. • Nature Communications
(2021)
Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets th...
DOAJ
Open Access (DOAJ)
DOI: 10.1038/s41467-021-21860-7
Ariel A. Hippen, Dalia K. Omran, Lukas M. Weber, Euihye Jung et al. • Genome Biology
(2023)
Abstract Background Single-cell gene expression profiling provides unique opportunities to understand tumor heterogeneity and the tumor microenvironment. Because of cost and feasibility, profiling bulk tumors remains the primary population-...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s13059-023-03077-7
Caroline W. Grant, Jerry Li, Swan Lin, Dana Nickens et al. • Clinical and Translational Science
(2025)
ABSTRACT Patient outcomes in advanced renal cell carcinoma (RCC) remain poor, with five‐year survival rates ranging from ~10% to 30%. Early projections of therapeutic outcomes could optimize precision medicine and accelerate drug developmen...
DOAJ
Open Access (DOAJ)
DOI: 10.1111/cts.70348
Solveig Badillo, Balázs Bánfai, Fabian Birzele, Iakov I. Davydov et al. • Clinical Pharmacology & Therapeutics
(2020)
In the last few years, machine learning (ML) and artificial intelligence have seen a new wave of publicity fueled by the huge and ever-increasing amount of data and computational power as well as the discovery of improved learning algorithm...
OPENALEX
cc-by-nc-nd
DOI: https://doi.org/10.1002/cpt.1796
PMC: 7189875
Heather Marriott, Renata Kabiljo, Guy P Hunt, Ahmad Al Khleifat et al. • Acta Neuropathologica Communications
(2023)
Abstract Amyotrophic lateral sclerosis (ALS) displays considerable clinical and genetic heterogeneity. Machine learning approaches have previously been utilised for patient stratification in ALS as they can disentangle complex disease lands...
DOAJ
Open Access (DOAJ)
DOI: 10.1186/s40478-023-01686-8